Inova Translational Medicine Institute
8081 Innovation Park Dr. Ste 700, Fairfax, VA, 22031-4867, United States
Overview
Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute that applies genomic and clinical information from individuals to develop innovative methods for personalized healthcare. ITMI is part of Inova Center for Personalized Health (ICPH), which connects researchers, clinicians, and consumers to integrate genomic research for patient care, prevention, and wellness. This approach enables individuals to live longer and transforms healthcare from reactive to predictive. Research studies at ITMI generate a large genomic and clinical data set that can be used by researchers in a variety of fields, from computational biology to psychology, and biomedical research applications. ITMI’s utilizes genomic information from an individual to understand the onset of disease, leading to the implementation of preventative medicine, and to increase successful outcomes while reducing adverse reactions to treatment.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Genetics
- Health Care
- Medical
Investment portfolio
- PierianDx
Participated · Series A · Jan 2016
PierianDx builds assay-agnostic interpretation technology and services to help providers, laboratories, and medical centers run next-generation sequencing (NGS) testing on site. The company pairs advanced interpretation software with a comprehensive genomic knowledgebase to empower clinicians to understand genetic variation and inform treatment decisions. PierianDx partners with industry leaders and medical facilities worldwide as they build or expand precision medicine programs. The firm was founded in 2014 as a technology-transfer spinout from Washington University in St. Louis and is headquartered in St. Louis. Management says the business is expanding commercially as more healthcare organizations seek to internalize NGS testing capabilities. The recent financing is intended to fund commercial expansion and continued product and team development to bring genomics into more clinical settings. PierianDx offers a SaaS clinical genomics informatics platform that enables the practice of clinical next-generation sequencing (NGS) as a standard of care and supports advanced molecular diagnostic laboratories. The company also operates a CAP- and CLIA-accredited laboratory and provides integrated reporting and decision-support across the clinical care spectrum. PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Leadership emphasizes adding clinical expertise and resources to drive adoption of clinical NGS globally. Management plans to accelerate commercial expansion across the U.S. and international markets including Europe, Asia, Australia, and Latin America. PierianDx was founded in 2014 out of Washington University in St. Louis. PierianDx provides genomic software and services to enable data-driven personalized medicine. Its flagship platform, Clinical Genomicist Workstation (CGW), delivers data-driven workflows for health systems, academic medical centers, and commercial labs to support genomic analysis, interpretation and reporting. Led by CEO Ted Briscoe, the company focuses on improving patient outcomes through precise genomic analysis. PierianDx said it will use the new funding to accelerate product development and expand sales, marketing and operations. The company raised $9.25M in a Series A to support these initiatives.
Team
No current team members are available.